Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors

NCT ID: NCT03734588

Last Updated: 2024-02-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 4 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-01-30
• Study Completion Date: 2023-01-19

Brief Summary

SPK-8016 is in development for the treatment of patients with inhibitors to FVIII. This Phase 1/2, open-label, non-randomized, dose-finding study to evaluate the safety, efficacy, and tolerability of SPK-8016 in adult males with severe hemophilia A and no measurable inhibitor against FVIII.

Conditions

Adeno-Associated Virus (AAV); Blood Coagulation Disorder; Blood Coagulation Disorders, Inherited; Coagulation Protein Disorders; Factor VIII (FVIII); Factor VIII (FVIII) Deficiency; Factor VIII (FVIII) Gene; Factor VIII (FVIII) Protein; Genetic Diseases, Inborn; Genetic Diseases, X-Linked; Gene Therapy; Gene Transfer; Hematologic Diseases; Hemorrhagic Disorders; Recombinant; Vector; Inhibitors

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

SPK-8016

All participants who meet the eligibility criteria will receive an outpatient single intravenous (i.v.) administration of SPK-8016.

Group Type: EXPERIMENTAL

SPK-8016

Intervention Type: GENETIC

adeno-associated viral vector

Interventions

SPK-8016

adeno-associated viral vector

Intervention Type: GENETIC

Eligibility Criteria

Inclusion Criteria

1. Be male and ≥18 years of age;

2. Have clinically severe hemophilia A, defined as:

1. <1% (<1 IU/dL) endogenous FVIII activity levels as historically documented by a certified laboratory or screening data results; OR

2. 1-2% (1-2 IU/dL) endogenous FVIII activity levels and > 10 bleeding events per year (in the last 52 weeks prior to screening); OR

3. 1-2% (1-2 IU/dL) endogenous FVIII activity levels and on prophylaxis;

3. Have had >150 exposure days (EDs) to any recombinant and/or plasma-derived FVIII concentrates or cryoprecipitates

4. Have no prior history of hypersensitivity or anaphylaxis associated with any FVIII or IV immunoglobulin administration

5. Have no measurable inhibitor against FVIII as assessed by central laboratory, have no confirmed history of clinically significant FVIII inhibitor, and no clinical signs or symptoms of decreased response to FVIII administration (Note: family history of inhibitors will not exclude study participation)

6. Agree to use reliable barrier contraception after the administration of SPK-8016 until notified by the Investigator.

Exclusion Criteria

1. Have active hepatitis B or C

2. Have significant underlying liver disease.

3. Have serological evidence of HIV-1 or HIV-2 with CD4 counts ≤200/mm3. Participants who are HIV-positive and stable, with an adequate CD4 count (>200/mm3) and undetectable viral load, and are on an antiretroviral drug regimen are eligible to enroll

4. Have detectable antibodies reactive with AAV-Spark capsid

5. Have history of chronic infection or other chronic disease

6. Have been dosed in a previous gene therapy research trial within the last 52 weeks or with an investigational drug within the last 12 weeks

7. Any concurrent clinically significant major disease (such as liver abnormalities or type I diabetes) or other condition that, in the opinion of the Investigator and/or Sponsor, makes the subject unsuitable for participation in the study;

8. Unable or unwilling to comply with the schedule of visits and study assessments described in the clinical protocol.

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Spark Therapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Tiffany Chang, MD

Role: STUDY_DIRECTOR

Spark Therapeutics, Inc.

Locations

Orthopaedic Institute for Children

Los Angeles, California, United States

Illinois Bleeding and Clotting Disorders Institute

Peoria, Illinois, United States

University of Michigan

Ann Arbor, Michigan, United States

Mississippi Center for Advanced Medicine

Madison, Mississippi, United States

Weill Cornell Medicine

New York, New York, United States

Oregon Health & Science University

Portland, Oregon, United States

Penn State Health

Hershey, Pennsylvania, United States

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

Jefferson University Hospitals

Philadelphia, Pennsylvania, United States

Hemophilia Center of Western Pennsylvania

Pittsburgh, Pennsylvania, United States

Virginia Commonwealth University School of Medicine

Richmond, Virginia, United States

Countries

United States

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

SPK-8016-101

Identifier Type: -

Identifier Source: org_study_id